Lista de obras - Jeanne M. Schilder - Dominio Público Uruguay

"What's in a name? That which we call a rose, by any other name.".

artículo científico publicado en 2002

A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study

artículo científico publicado en 2009

A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer

artículo científico publicado en 2010

A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study

artículo científico publicado en 2007

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

artículo científico publicado en 2015

A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study

artículo científico publicado en 2014

Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.

artículo científico publicado en 2009

Cell Origins of High-Grade Serous Ovarian Cancer

Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer.

artículo científico publicado en 2012

Epigenetic resensitization to platinum in ovarian cancer

artículo científico publicado en 2012

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

artículo científico publicado en 2008

Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer ⬇️

artículo científico publicado el 30 de agosto de 2012

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.

artículo científico publicado en 2008

Indiana University experience in the management of vaginal cancer

artículo científico publicado en 2009

Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group ⬇️

artículo científico publicado el 1 de febrero de 2011

Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy

artículo científico publicado en 2002

Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study

artículo científico publicado en 2005

Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study

artículo científico publicado en 2005

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study

artículo científico publicado en 2012

Prognosis of patients who relapse after fertility-sparing surgery in epithelial ovarian cancer

artículo científico publicado en 2007

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

artículo científico publicado en 2016

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study

artículo científico publicado en 2018

Representations of vaginal symptoms in cervical cancer survivors

artículo científico publicado en 2009

Stage Ia-IIa cancer of the cervix

artículo científico publicado en 2003

The Morphology Index: Predictive value of malignancy among clinicians at various levels of training ⬇️

artículo científico publicado el 6 de julio de 2012

Treatment delays using an automated afterloading low-dose-rate brachytherapy system

artículo científico publicado en 2009

Lista de obras de Jeanne M. Schilder

"What's in a name? That which we call a rose, by any other name.".

A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study

A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer

A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study

Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.

Cell Origins of High-Grade Serous Ovarian Cancer

Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer.

Epigenetic resensitization to platinum in ovarian cancer

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer ⬇️

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.

Indiana University experience in the management of vaginal cancer

Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group ⬇️

Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy

Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study

Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study

Prognosis of patients who relapse after fertility-sparing surgery in epithelial ovarian cancer

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study

Representations of vaginal symptoms in cervical cancer survivors

Stage Ia-IIa cancer of the cervix

The Morphology Index: Predictive value of malignancy among clinicians at various levels of training ⬇️

Treatment delays using an automated afterloading low-dose-rate brachytherapy system